ArticleLeukemia2021
Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis.
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Detection of minimal residual disease by next generation sequencing in AL amyloidosis.Blood cancer journal · 2021Trial
- Monitoring of Treatment Response in Light-chain Cardiac Amyloidosis-Does Echocardiography Have a Role?Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study.Advances in therapy · 2026Article
- Impact of early minimal residual disease assessment on the outcomes of patients with systemic light chain amyloidosis.Annals of medicine · 2025Article
- Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.Blood cancer journal · 2022Observational
- Cardiac Amyloidosis.Heart failure clinics · 2022Review
- Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.Journal of cancer research and clinical oncology · 2022Article
- Article
- Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.